ABZA Abzena

TIDMABZA

RNS Number : 7440Y

Abzena PLC

23 August 2018

Abzena plc

Notice of AGM

Cambridge, UK, 23 August 2018 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that its Annual General Meeting (AGM) will be held at 10:00am on Monday, 17 September 2018 at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES.

A copy of the Notice of AGM, Form of Proxy, and 2018 Annual Report are available at

http://www.abzena.com/about/investor-information/documents/

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive Officer Julian 
    Smith, Chief Financial Officer                     +44 1223 903498 
   Numis (Nominated Adviser and Broker) 
    James Black / Paul Gillam / Duncan Monteith        +44 20 7260 1000 
 
   N+1 Singer (Joint Broker) 
    Aubrey Powell / Liz Yong                           +44 20 7496 3000 
   Instinctif Partners                                 +44 20 7457 2020 
    Melanie Toyne Sewell / Rozi Morris /                abzena@instinctif.com 
    Alex Shaw 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

   --      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --      Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --      Proprietary site-specific conjugation technologies and novel payloads for ADC development; 
   --      GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and 
   --      GMP analytical services for biopharmaceutical manufacturing projects. 

For more information, please see www.abzena.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOASEMFIDFASELA

(END) Dow Jones Newswires

August 23, 2018 11:48 ET (15:48 GMT)

Abzena (LSE:ABZA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Abzena (LSE:ABZA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024